FLT3 and acute myeloid leukemia: One phase 1/2 study is currently evaluating the combination of quizartinib, decitabine, and venetoclax in patients with untreated or relapsed AML/MDS (NCT03661307); another phase 1/2 study is investigating gilteritinib together with azacitidine and venetoclax in relapsed/refractory FLT3-mutated AML and high-risk MDS (NCT04140487).